Squamous cell carcinoma - Plattenepithelkarzinomhttps://en.wikipedia.org/wiki/Squamous_cell_carcinoma
Plattenepithelkarzinom (Squamous cell carcinoma) Vulgo rubra, scandens, incrassata laesio in cute solis exposita est. Quaedam sunt solidae nodulae durae et testudine conformatae sicut keratoacanthomas. Potest fieri exulceratio et sanguinis. Cum plattenepithelkarzinom (squamous cell carcinoma) dictum non, massa in magna dictum consequat. Cellula squamosa est secunda cancer cutis frequentissima. Periculosum est, sed non tam periculosum quam melanoma. Post biopsy, surgice tolletur.

Diagnosis et curatio
#Dermoscopy
#Skin biopsy
☆ In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
  • Squamous cell carcinoma well differentiated An keratosis actinensis adjacent observatur.
  • Keratoacanthoma
  • Keratoacanthoma
  • Plattenepithelkarzinom (Squamous cell carcinoma) Antebrachium
  • Si vulnus diu non sanat, suspecta est cancer cutis.
  • Si vulnus diu non sanat, suspecta est cancer cutis.
References Squamous Cell Skin Cancer 28722968 
NIH
Squamous cell carcinoma (SCC) est secunda cancer cutis frequentissima in Civitatibus Foederatis Americae, post basal cell carcinoma. Solet ab laesionibus precariis, quae actinic keratosis dicuntur, et in alias partes corporis diffundi potest. Causa principalis est expositionis ultraviolatarum (UV) radiorum solis, qui per tempus accumulat. Curatio chirurgicam amotionem implicat, praesertim SCC in capite et collo. Lorem radialis optio est aegris senioribus vel illis qui chirurgicam habere non possunt. Immunosuppressionis periculum auget SCC. Etsi rara, SCC diffundi potest, praesertim in patientibus systematibus immunibus debilitatis. Regulares reprehendo-ups et tutela solis momenti sunt pro illis cum SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
 Cutaneous Squamous Cell Carcinoma: From Biology to Therapy 32331425 
NIH
Cutaneous squamous cell carcinoma (CSCC) Secundus cancer in hominibus frequentissimus est, et eius numeri ascendunt. Quamvis CSCC mores benignos orci exhibere soleant, potest tam localiter quam in alias corporis partes diffundi. Docti notaverunt vias specificas in progressu CSCC implicatas, ad novas curationes ducendas. Princeps numerus mutationum et periculum auctus in immunosuppresso aegroti progressionem immunotherapyrum suasit. Haec recensio spectat ad radices geneticae CSCC et curationes ultimas moleculas specificas et systema immune.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors